Press Release: SteadyMed : SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN RAMON, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2018.
Read full article »
SteadyMed develops and commercializes drug product candidates for the subcutaneous treatment of pulmonary arterial hypertension.
Read more